Clinical evaluation of mezlocillin.

Antimicrobial Agents and Chemotherapy
H Thadepalli, B Rao

Abstract

The safety and efficacy of intravenous mezlocillin were determined in 25 patients with aerobic, anaerobic, and mixed infections. Included were pleuropulmonary, urinary tract, skin, and soft-tissue infections, osteomyelitis, and abdominal and breast abscess. Nineteen patients (76%) were cured without recurrence as determined by clinical and bacteriological parameters. In three, the infection recurred (12%); two patients failed (8%), and in one, it was indeterminate (4%). No serious adverse effects were noted except for severe thrombophlebitis in three (12%) patients. Our preliminary data suggest that mezlocillin is a safe (except for thrombophlebitis) and effective antibiotic in the treatment of aerobic anaerobic, and mixed infections.

References

Mar 1, 1979·Antimicrobial Agents and Chemotherapy·H ThadepalliD Webb
Jan 1, 1977·Antimicrobial Agents and Chemotherapy·G P Bodey, T Pan
Oct 1, 1976·Antimicrobial Agents and Chemotherapy·V L Sutter, S M Finegold

❮ Previous
Next ❯

Citations

Jan 1, 1982·Indian Journal of Pediatrics·H Thadepalli
Aug 1, 1981·Antimicrobial Agents and Chemotherapy·P C FuchsE H Gerlack
Jan 1, 1983·Scandinavian Journal of Infectious Diseases·B BjorvatnS G Gundersen
Nov 1, 1986·Zentralblatt Für Bakteriologie, Mikrobiologie, Und Hygiene. Series A, Medical Microbiology, Infectious Diseases, Virology, Parasitology·H MittermayerG Stanek
Jun 10, 2008·Anaerobe·Emenike Ribs K Eribe, Ingar Olsen
Nov 1, 1982·Pharmacotherapy·R V McCloskeyG R Aronoff

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.